Zydus Lifesciences, Beihai Biotech collaborate for US market entry
Zydus Lifesciences Global FZE and Zhuhai Beihai Biotech Co. have entered into an exclusive licensing and commercialization agreement for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product, for the US market. Under the agreement, Beihai Biotech will manufacture and supply BEIZRAY, while Zydus will handle commercialization in the US. Beihai Biotech will receive upfront payments, sales-based milestones, and a share of net profits from BEIZRAY sales in the US. BEIZRAY, already approved in the US, is indicated for treating cancers like breast, lung, prostate, and head and neck. It is an improved docetaxel formulation reducing adverse events. The Docetaxel Injection market volume is approximately 531,000 units annually in the USA.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Zydus Lifesciences publishes news
Free account required • Unsubscribe anytime